clinical trial · NCT07622108
Treatment of Active Thyroid Eye Disease With MHB018A in a Randomized, Placebo-Controlled Study
Minghui Pharmaceutical (Hangzhou) Ltd·phase3·not yet recruiting·n = 84
Thyroid Eye Disease, TEDMHB018AMHB018A placebo
brief summary
The primary objective of this study is to evaluate the efficacy of MHB018A injection compared with placebo in participants with active moderate-to-severe TED.
started
Dec 1, 2026
primary completion
Jul 1, 2028
completion
Jul 1, 2029
last updated
Jun 2, 2026
detailed description
The primary objective of this study is to evaluate the efficacy of MHB018A injection compared with placebo in participants with active moderate-to-severe TED.
official title
A Phase III, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of MHB018A Injection Treatment in Subjects With Active Moderate to Severe Thyroid Eye Disease.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol